The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Phase II study of isatuximab, pomalidomide and dexamethasone in lenalidomide-exposed R/R myeloma
Evangelos Terpos, MD, PhD, University of Athens School of Medicine, Athens, Greece, comments on the results of a Phase II study (NCT05298683) evaluating the combination of isatuximab, pomalidomide, and dexamethasone in relapsed/refractory (R/R) multiple myeloma (MM) patients with one prior line of lenalidomide-containing therapy. Dr Terpos highlights that the study achieved a response rate of approximately 70% and is investigating the efficacy of isatuximab as a maintenance therapy every 15 days versus monthly in patients once patients achieve a very good partial response (VGPR). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
This study is a Phase II study that we wanted to evaluate the combination of isatuximab, pomalidomide, and dexamethasone that has been approved but from the third line and beyond. We wanted to check what is the value of this combination at second line in patients who have been exposed to lenalidomide.
This study has also another important point that after the patients have achieved a very good partial response...
This study is a Phase II study that we wanted to evaluate the combination of isatuximab, pomalidomide, and dexamethasone that has been approved but from the third line and beyond. We wanted to check what is the value of this combination at second line in patients who have been exposed to lenalidomide.
This study has also another important point that after the patients have achieved a very good partial response. We randomize them to receive isatuximab as standard every 15 days or isatuximab monthly in order to see if with a so-called maintenance type isatuximab can be given monthly like daratumumab for example. So we present here the first results of the first 40 patients of the study where we have seen that the response rate is what we expected around 70% and of course the median PFS has not been reached yet but we are expecting with the new updates of the study to see exactly what the median PFS will be for this specific subgroup of patients where the majority of patients were lenalidomide refractory.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Amgen: Honoraria, Other: Travel expenses, Research Funding; AstraZeneca: Honoraria, Other: Travel expenses; BMS: Honoraria; EUSA Pharma: Honoraria, Other: Travel expenses; Janssen: Honoraria, Research Funding; GSK: Honoraria, Research Funding; Menarini/Stemline: Honoraria; Pfizer: Honoraria; Sanofi: Honoraria, Other: Travel expenses, Research Funding; Takeda: Honoraria, Other: Travel expenses, Research Funding; Novartis: Honoraria; Antengene: Honoraria, Research Funding; Swixx: Honoraria.
